Hikma Should Revisit Investigations, FDA Warning Says
This article was originally published in PharmAsia News
Continued problems at a Portuguese plant have prompted the U.S. FDA to urge Hikma to make a global reassessment of its manufacturing processes.
You may also be interested in...
FDA reported 1,276 drug recalls last year, the third-highest level ever. Inspections of pharmacies that compounded purportedly aseptic injectables drove the numbers, but pharmaceutical manufacturers also contributed as they struggled with particulates, precipitation and other issues.
Pharmaceutical enterprises have become so complex that some sites with quality problems can’t find the root cause because they no longer know who their key experts are or where to find them, one industry expert says. Regardless of why they happen, inadequate investigations continue to be the most frequently cited GMP concern in FDA warning letters year after year.
An inflection point arrives as US public sector pharma manufacturing hits 'warp speed' in COVID-19 crisis.